Show simple item record

dc.contributor.authorParisini, Irene
dc.contributor.authorCheng, Sean J
dc.contributor.authorSymons, Digby
dc.contributor.authorMurnane, Darragh
dc.date.accessioned2014-06-03T15:30:27Z
dc.date.available2014-06-03T15:30:27Z
dc.date.issued2014-05
dc.identifier.citationParisini , I , Cheng , S J , Symons , D & Murnane , D 2014 , ' Potential of a cyclone prototype spacer to improve in vitro dry powder delivery ' , Pharmaceutical Research , vol. 31 , no. 5 , pp. 1133-1145 . https://doi.org/10.1007/s11095-013-1236-8
dc.identifier.issn0724-8741
dc.identifier.otherPURE: 2479729
dc.identifier.otherPURE UUID: 1ddc00b2-36b9-43bf-b5e7-86309105dcad
dc.identifier.otherScopus: 84902292014
dc.identifier.urihttp://hdl.handle.net/2299/13606
dc.descriptionCopyright The Author(s) 2013. This article is published with open access at Springerlink.com. This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited
dc.description.abstractPurpose: Low inspiratory force in patients with lung disease is associated with poor deagglomeration and high throat deposition when using dry powder inhalers (DPIs). The potential of two reverse flow cyclone prototypes as spacers for commercial carrierbased DPIs was investigated. Methods: Cyclohaler®, Accuhaler® and Easyhaler® were tested with and without the spacers between 30-60 Lmin-1. Deposition of particles in the next generation impactor and within the devices was determined by high performance liquid chromatography. Results: Reduced induction port deposition of the emitted particles from the cyclones was observed due to the high retention of the drug within the spacers (e.g. salbutamol sulphate (SS): 67.89 ± 6.51 % at 30 Lmin-1 in Cheng 1). Fine particle fractions of aerosol as emitted from the cyclones were substantially higher than the DPIs alone. Moreover, the aerodynamic diameters of particles emitted from the cyclones were halved compared to the DPIs alone (e.g. SS from the Cyclohaler® at 4 kPa: 1.08 ± 0.05 μm vs. 3.00 ± 0.12 μm, with and without Cheng 2, respectively) and unaltered with increased flow rates. Conclusion: This work has shown the potential of employing a cyclone spacer for commercial carrier-based DPIs to improve inhaled drug delivery.en
dc.language.isoeng
dc.relation.ispartofPharmaceutical Research
dc.titlePotential of a cyclone prototype spacer to improve in vitro dry powder deliveryen
dc.contributor.institutionDepartment of Pharmacy
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionCentre for Research into Topical Drug Delivery and Toxicology
dc.contributor.institutionPharmaceutics
dc.contributor.institutionAirway Group
dc.contributor.institutionPharmaceutical Analysis and Product Characterisation
dc.description.statusPeer reviewed
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.1007/s11095-013-1236-8
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record